



PRESS RELEASE

NEW CONTRACTS GENERATE £3 MILLION OF ADDITIONAL REVENUE FOR EDEN BIODESIGN

Contracts signed in the UK, Continental Europe and Asia

Liverpool, UK and Research Triangle Park, NC, USA; 25 November 2008: Eden Biodesign Ltd., an expert provider of biopharmaceutical process development and cGMP manufacturing services, reports today on the successful signature of three separate contracts with a total initial value of £2.97 million. The contracts cover a combination of development and cGMP manufacturing services. In a further demonstration of Eden Biodesign's continued international growth, two of the contracts are with new clients, one based in Asia and the other in Continental Europe. The third contract is for a new therapeutic with an existing UK client. All three could lead to significant further sales.

Dr. Crawford Brown, CEO, commented: "We are delighted to be able to announce these significant new contracts at a time when the industry is facing challenging market conditions. We put our success down to our growing track record, particularly overseas, and we are considering accelerating our North American expansion plans. We are optimistic that we will be able to make further announcements of several more significant contract wins in the next few weeks and several exciting technology collaborations and partnerships in the coming months."

Dr Roger Lias, Group Commercial Director and President of Eden Biodesign's North American subsidiary, added: "As we continue to expand our global business development and marketing reach we are able to maintain a robust project pipeline. Our world class cGMP production facilities, the depth of our service offering and the breadth of our manufacturing capabilities covering all major biopharmaceutical production platforms including mammalian cell culture, microbial fermentation and production of viral products mean that we continue to see attractive market opportunities for recombinant therapeutics and a variety of vaccine products. We are especially encouraged by continued strong interest in North America".

Recruitment continues as planned to support the growing client base and expanding project portfolio. World class scientists, engineers and specialists are being sought and appointed for key positions within the development and manufacturing teams.

- Ends -



For further information contact:

Media enquiries:

Liz Wyatt, De Facto Communications Ltd
+44 (0)20 7861 3838
Email l.wyatt@defacto.com

Business enquiries:

Roger Lias, Ph.D., Group Commercial Director, Eden Biodesign
(919) 349-2770
Email roger.lias@edenbiodesign.com

Notes to editors:

Eden Biodesign

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com.

In August of this year, we announced a marketing services agreement with Human Genome Sciences, Inc. for large scale cGMP manufacturing services, providing a seamless range of services for clients from process development to 20,000L scale production.

Next month, Dr. Roger Lias will be presenting at the IBC's Biopharmaceutical Manufacturing Development Summit in Durham, NC and in January 2009 we will be exhibiting at Peptalk 2009 in Coronado, CA and also Phacilitate's Cell & Gene Therapy & Vaccine Forum, Washington DC.